Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery

Stage IV Lung Cancer AJCC v8 Clinical Trial

Official title:

A Phase I/II Study Evaluating the Safety and Pharmacokinetics of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Lung Cancer During Surgical Procedures

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03582124
• Other study ID #: IRB-41302
• Secondary ID: NCI-2018-00494LU
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: July 19, 2018
• Est. completion date: February 2027

Study information

• Verified date: February 2024
• Source: Stanford University
• Contact: Roan C Raymundo
• Phone: 650-721-4071
• Email: rcraymun[@]stanford.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase I/II trial studies the best dose and timing of panitumumab-IRDye800 in detecting cancer in participants with lung cancer during the surgery. Panitumumab-IRDye800 is a combination of the antibody drug panitumumab and IRDye800CW, an investigational dye that can be seen using a special camera. Panitumumab-IRDye800 may attach to tumor cells and make them more visible during surgery in patients with lung cancer.

Description:

PRIMARY OBJECTIVES:

I. To determine the optimal dose and timing of panitumumab IRDye800 infusion for identifying lung cancer compared to surrounding normal tissue in the ex vivo setting as measured by tumor to background ratio.

SECONDARY OBJECTIVES:

I. Determine the safety and tolerability of the panitumumab IRDye800 as an imaging agent in subjects undergoing resection of lung cancer.

II. Determine whether the primary lung tumor or positive lymph nodes can be detected by near-infrared (NIR) fluorescence imaging with panitumumab IRDye800 but not by white light imaging.

OUTLINE: This is a phase I, dose-escalation study of panitumumab-IRDye800 followed by a phase II study.

Participants receive panitumumab- IRDye800 intravenously (IV) over 60 minutes on day 0, and then undergo NIR and surgery within 1-5 days.

After completion of study treatment, participants are followed up for up to 30 days.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: February 2027
• Est. primary completion date: February 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

• Patients with lung nodule or mass concerning for malignancy, either primary lung cancer or lung metastases, whether or not it is biopsy-proven

• Patients scheduled to undergo planned standard of care surgical resection for a lung nodule or mass with diagnostic and/or curative intent for lung cancer

• Karnofsky performance status of at least 70% or Eastern Cooperative Oncology Group (ECOG)/Zubrod level 0-2

• Hemoglobin = 9 gm/dL

• White blood cell count > 3000/mm^3

• Platelet count = 100,000/mm^3

• Serum creatinine = 1.5 times upper reference range

Exclusion Criteria:

• Received an investigational drug within 30 days prior to first dose of panitumumab-IRDye800

• Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment

• History of infusion reactions to monoclonal antibody therapies

• Pregnant or breastfeeding

• Magnesium or potassium lower than the normal institutional values

• Subjects receiving class IA (quinidine, procanamide) or class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents

• Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis

• Prisoners, institutionalized individuals, and patients unable to consent for themselves

Related Conditions & MeSH terms

• Lung Carcinoma
• Lung Neoplasms
• Metastatic Malignant Neoplasm in the Lung
• Neoplasms
• Stage IV Lung Cancer AJCC v8
• Stage IVA Lung Cancer AJCC v8
• Stage IVB Lung Cancer AJCC v8

Intervention

Procedure:
• Near-Infrared Fluorescence Imaging
Undergo imaging

Drug:
• Panitumumab-IRDye800
Given IV

Other:
• Pharmacokinetic Study
Correlative studies

Procedure:
• Therapeutic Conventional Surgery
Undergo surgery

Locations

Country	Name	City	State
United States	Stanford University, School of Medicine	Palo Alto	California

Sponsors (1)

Lead Sponsor	Collaborator
Eben Rosenthal

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tumor to background ratio (TBR), measured in ex vivo tissues	The TBR is defined as the near-infrared fluorescence signal of tumor or lymph node tissue compared to normal adjacent tissue measured in ex vivo tissues. Outcomes will be reported as the TBR (mean) and standard deviation for each dose group and timing group (1-2 days or 3-5 days prior to surgery).	Up to 1 year
Secondary	Number of Grade 2 or higher AEs determined to be clinically significant and definitely, probably or possibly related to study drug		Up to 30 days
Secondary	Metastatic lesion detection by Panitumumab-IRDye800 versus standard assessments	Intraoperative near-infrared fluorescence imaging with panitumumab-IRDye800 will be compared to conventional white light visualization and ex vivo histopathology methods to identify metastatic lesions. Outcomes will be reported as the number of metastatic lesions detected by both near-infrared fluorescence imaging and histopathology, and each method alone.	Up to 1 year
Secondary	Tumor-positive lymph node detection by Panitumumab-IRDye800 versus standard assessments	Intraoperative near-infrared fluorescence imaging with panitumumab-IRDye800 will be compared to conventional white light visualization and ex vivo histopathology methods to identify tumor-positive lymph nodes. Outcomes will be reported as the number of tumor-positive lymph nodes detected by both near-infrared fluorescence imaging and histopathology, and each method alone.	Up to 1 year
Secondary	Residual disease detection by Panitumumab-IRDye800 versus standard assessments	Intraoperative near-infrared fluorescence imaging with panitumumab-IRDye800 will be compared to conventional white light visualization and ex vivo histopathology methods to identify residual disease at resection margins. Outcomes will be reported as the number of positive-margins detected by both near-infrared fluorescence imaging and histopathology, and each method alone.	Up to 1 year